Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Meritxell DelaVarga
Variability in Non-Nucleoside Reverse Transcriptase and Protease Inhibitors Concentrations Among HIV-infected Adults in Routine Clinical Practice
British Journal of Clinical Pharmacology
Pharmacology
Related publications
Mechanisms of Inhibition of HIV Replication by Non-Nucleoside Reverse Transcriptase Inhibitors
Virus Research
Cancer Research
Virology
Infectious Diseases
Multicenter Study of Skin Rashes and Hepatotoxicity in Antiretroviral-Naïve HIV-positive Patients Receiving Non-Nucleoside Reverse-Transcriptase Inhibitor Plus Nucleoside Reverse-Transcriptase Inhibitors in Taiwan
PLoS ONE
Multidisciplinary
Non-Nucleoside Reverse Transcriptase Inhibitor Outcomes Among Combination Antiretroviral Therapy-Treated Adults in Botswana
AIDS
Infectious Diseases
Allergy
Immunology
New Indolylarylsulfones as Highly Potent and Broad Spectrum HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
European Journal of Medicinal Chemistry
Medicine
Organic Chemistry
Drug Discovery
Pharmacology
Weight Gain Among Treatment‐naïve Persons With HIV Starting Integrase Inhibitors Compared to Non‐nucleoside Reverse Transcriptase Inhibitors or Protease Inhibitors in a Large Observational Cohort in the United States and Canada
Journal of the International AIDS Society
Environmental
Public Health
Infectious Diseases
Occupational Health
Anti-Hiv Drugs and Resistance: Inhibitors of HIV-1 Reverse Transcriptase and Protease
Nucleoside Reverse Transcriptase Inhibitors Prevent HIV Protease Inhibitor-Induced Atherosclerosis by Ubiquitination and Degradation of Protein Kinase C
American Journal of Physiology - Cell Physiology
Physiology
Cell Biology
Design, Synthesis, and Evaluation of Diarylpyridines and Diarylanilines as Potent Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors
Journal of Medicinal Chemistry
Drug Discovery
Molecular Medicine
FEP-Guided Selection of Bicyclic Heterocycles in Lead Optimization for Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase
